Sanguinarina Hydrosulfate + Helerythrina Hydrosulfate (Sanguinarini hydrosulfas + Heleritrini hydrosulfas)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other antimicrobial, antiparasitic and anthelmintic agents

Included in the formulation
  • Sanguirythrin®
    pills inwards 
    FARMTSENTR VILAR, ZAO     Russia
  • Sanguirythrin®
    solution locally externally 
    FARMTSENTR VILAR, ZAO     Russia
    • АТХ:

    J.01.X.X   Other antibacterial drugs

    Pharmacodynamics:

    Antimicrobial action is due to the suppression of bacterial nuclease, a violation of the permeability of cell walls, fission partitions, nucleotide structure.

    Pharmacokinetics:

    Not studied.

    Indications:

    Inside. In the complex therapy of acute and chronic purulent-inflammatory diseases: OCI (shigellosis, salmonellosis, food toxic infections); wound infections and various infectious complications caused by pathogenic microflora (convalescent bacteriocarrier); diseases associated with the violation of normal microflora (dysbiosis), as well as diseases caused by pathogenic fungi (pharyngicosis, candidiasis, microsporia).

    As part of combination therapy - Sensitive and motor disorders associated with diseases and traumatic injuries of the nervous system (poliomyelitis, cerebral palsy).

    Outwardly. Prevention of purulent-inflammatory skin diseases in newborns and wound infection in surgical patients. Infectious-inflammatory skin diseases (including infected wounds); pyoderma, eczema, dermatomycosis, onychomycosis, burns.

    ICD-10

    I.A00-A09.A02.9   Salmonella infection, unspecified

    I.A00-A09.A02.8   Other specified salmonella infection

    I.A00-A09.A02.0   Salmonella enteritis

    I.A00-A09.A02   Other salmonella infections

    I.A00-A09.A05.9   Bacterial food poisoning, unspecified

    I.A00-A09.A05.8   Other specified bacterial food poisoning

    I.A00-A09.A05.0   Staphylococcal food poisoning

    I.A00-A09.A05   Other bacterial food poisoning

    I.B35-B49.B37.9   Candidiasis, unspecified

    I.B35-B49.B37.8   Candidiasis of other localizations

    I.B35-B49.B37.2   Candidiasis of skin and nails

    I.B35-B49.B37.0   Candidiasis stomatitis

    I.B35-B49.B37   Candidiasis

    VIII.H65-H75.H67.8 *   Otitis media in other diseases classified elsewhere

    VIII.H65-H75.H67.0 *   Otitis media in bacterial diseases classified elsewhere

    VIII.H65-H75.H67 *   Otitis media in diseases classified elsewhere

    VIII.H65-H75.H66.9   Other otitis media, unspecified

    VIII.H65-H75.H66.3   Other chronic purulent otitis media

    VIII.H65-H75.H66.1   Chronic tubotimponal purulent otitis media

    VIII.H65-H75.H66.0   Acute suppurative otitis media

    VIII.H65-H75.H66   Purulent and unspecified otitis media

    VIII.H60-H62.H62.4 *   Otitis externa in other diseases classified elsewhere

    VIII.H60-H62.H62.3 *   External otitis in other infectious and parasitic diseases classified elsewhere

    VIII.H60-H62.H62.2 *   External otitis with fungal infections

    VIII.H60-H62.H62.1 *   Otitis externa in viral diseases classified elsewhere

    VIII.H60-H62.H62.0 *   Otitis externa in bacterial diseases classified elsewhere

    VIII.H60-H62.H60.9   External otitis, unspecified

    VIII.H60-H62.H60.8   Other external otitis media

    VIII.H60-H62.H60.3   Other infectious external otitis media

    X.J00-J06.J03.8   Acute tonsillitis caused by other specified pathogens

    X.J00-J06.J03.0   Streptococcal tonsillitis

    X.J00-J06.J03   Acute tonsillitis

    XXI.Z40-Z54.Z48.9   Subsequent surgical care, unspecified

    XX.Y83-Y84.Y83.9   Surgical operation, unspecified

    XX.Y83-Y84.Y83.8   Other Surgery

    Contraindications:

    Hypersensitivity, liver and / or kidney disease with impaired function, epilepsy. For oral administration additionally: hyperkinesis, bronchial asthma, ischemic heart disease. For external use additionally: Fungal skin lesions with phenomena of eczematism.

    Carefully:Pregnancy, lactation, children under 1 year.
    Pregnancy and lactation:

    Application during pregnancy and during lactation is possible after consultation with the attending physician.

    Dosing and Administration:

    Inside after eating.Adults 10 mg 3-4 times a day (if necessary, the daily dose can be increased to 45 mg). The duration of the course of treatment depends on the nosological form and severity of the disease and on average is:

    at OCI (shigellosis, salmonellosis, food poisoning) - 5-7 days (if necessary, up to 10 days);

    with dysbacteriosis - up to 10-14 days;

    at bacteriocarrier (bacterial release) - 7-14 days;

    with pharyngomycosis and candidiasis - up to 14 days;

    with microsporia - 4-5 weeks.

    Outwardly. The sponge is cut to the size of the wound and applied to the entire wound surface, then closed with a dry aseptic dressing. In the presence of a wound cavity (wounds after opening abscesses, phlegmon, suppuration of postoperative wounds), after the appropriate treatment, insert the strips of the plate into the cavity, loosely tampon, place an additional plate on top and cover the wound with a sterile napkin or bandage. Dressings are performed after 1-2 days, depending on the condition of the wound and the degree of resorption of the plate. Indication for changing the dressing is full or partial lysis of the plate. The course of treatment and the number of dressings depend on the speed of healing.

    Children inside.1-3 years - 5 mg for each year of life, maximum doses: 1 year - 5 mg / day, 2 years - 5 mg 1-2 times a day, 3 years - 5 mg 2-3 times a day. 4 years-10 years - 5 mg 3-4 times a day, the maximum daily dose of 20 mg. 11-15 years - 5-10 mg 3 times a day, the maximum daily dose - 30 mg.

    Side effects:

    Allergic reactions. For oral administration additionally: nausea, vomiting, abdominal pain. For external use additionally: burning sensation or soreness when applied to the wound surface (eliminated by adding 0.5% solution of novocaine).

    Overdose:

    Symptoms (if ingested): nausea, vomiting, abdominal pain, dizziness, headache.

    Treatment: gastric lavage.

    Interaction:

    Outwardly it is possible to use a combination in combination with procaine, trimecaine.

    Other clinically significant interactions are not described.

    Special instructions:

    FDA refers the sanguine to unsafe herbs for use as a component of food, as part of beverages and as a medicinal product.

    Sanguinarin and chelerythrine in the form of components and combinations are not represented in the United States Pharmacopeia. Helerythrin and its combination with sanguinarine are not represented in the Pharmacopoeia of Great Britain.Sanguinarin found 39 CIs in the Cochrane Library devoted to the study of the effectiveness of sanguinarine in dentistry (prevention of plaque formation, treatment of periodontitis, gingivitis).

    Tablets can be used to prepare an aqueous solution. To reduce side effects, it is recommended to appoint after eating, along with sugar or syrup.

    0.05% and 0.5% of sanguinarine is inferior to chlorhexidine in preventing the formation of dental plaque and the development of gingivitis. 0.5% sanguinarin (but not 0.05% sanguinarin) delays the development of gingivitis in comparison with placebo.
    Instructions
    Up